Evidence map›Paper›PMID 32266056›Full record

ReviewCell & bioscience2020

Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.

Fei Xu, Lixin Na, Yanfei Li, Linjun Chen

RetractedOpen access · goldAbstract readReviewRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell & bioscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 268 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
268citing papers in PubMed, 2 pooled it
35.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

268 citing papers in PubMed, 2 syntheses or guidelines pooled it, 539 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

208 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fei Xu1Department of Microbiology and Immunology, Shanghai University of Medicine & Health Sciences, 279 Zhouzhu Rd, Shanghai, 201318 China.
Lixin NaCollaborative Innovation Center of Shanghai University of Medicine & Health Sciences, Shanghai, 201318 China.
Yanfei Li3Department of Inspection and Quarantine, Shanghai University of Medicine & Health Sciences, Shanghai, 201318 China.
Linjun Chen3Department of Inspection and Quarantine, Shanghai University of Medicine & Health Sciences, Shanghai, 201318 China.
Shanghai University of Medicine and Health Sciences · CN

Funding

Gulf Research Program (US) B1-0200-19-309178Gulf Research Program (US) B1-0200-19-311144Innovative Research Group Project of the National Natural Science Foundation of China (CN) 8187120707
6 · The paper itself

Abstract

The PI3 K/AKT/mTOR signalling pathway plays an important role in the regulation of signal transduction and biological processes such as cell proliferation, apoptosis, metabolism and angiogenesis. Compared with those of other signalling pathways, the components of the PI3K/AKT/mTOR signalling pathway are complicated. The regulatory mechanisms and biological functions of the PI3K/AKT/mTOR signalling pathway are important in many human diseases, including ischaemic brain injury, neurodegenerative diseases, and tumours. PI3K/AKT/mTOR signalling pathway inhibitors include single-component and dual inhibitors. Numerous PI3K inhibitors have exhibited good results in preclinical studies, and some have been clinically tested in haematologic malignancies and solid tumours. In this review, we briefly summarize the results of research on the PI3K/AKT/mTOR pathway and discuss the structural composition, activation, communication processes, regulatory mechanisms and biological functions of the PI3K/AKT/mTOR signalling pathway in the pathogenesis of neurodegenerative diseases and tumours.

Indexed as

Ischaemic brain injuryNeurodegenerative diseasesPI3K/AKT/mTOR signalling pathwayRegulatory mechanismTumour

Identifiers

PMID32266056
PMCPMC7110906
OpenAlexW3014459671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.